Patents by Inventor Tetsuhiro Soeda
Tetsuhiro Soeda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059795Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: October 27, 2023Publication date: February 22, 2024Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20230348621Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.Type: ApplicationFiled: July 5, 2023Publication date: November 2, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kunihiro Hattori, Tetsuo Kojima, Hiroyuki Saito, Taro Miyazaki, Tetsuhiro Soeda
-
Publication number: 20230212315Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: December 15, 2022Publication date: July 6, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20230183376Abstract: Production was attempted for antibodies that neutralize the activity of a bispecific antibody having F.VIII function-substituting activity, for use in a method for measuring the reactivity of F.VIII in the presence of a bispecific antibody having F.VIII function-substituting activity. As a result, it was discovered that by using the produced antibodies, F.VIII activity in the plasma of a hemophilia A patient can be evaluated accurately by performing APTT-based one-stage clotting assay on a wide range of bispecific antibodies having F.VIII function-substituting activity. It was also discovered that F.VIII inhibitor titer in the plasma of a hemophilia A patient carrying F.VIII inhibitor can be evaluated accurately by APTT-based Bethesda assay.Type: ApplicationFiled: May 21, 2021Publication date: June 15, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tetsuhiro Soeda, Jinki Hadano
-
Publication number: 20220267470Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor DC/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: April 26, 2022Publication date: August 25, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20220213217Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.Type: ApplicationFiled: March 21, 2022Publication date: July 7, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kunihiro Hattori, Tetsuo Kojima, Hiroyuki Saito, Taro Miyazaki, Tetsuhiro Soeda
-
Publication number: 20210380717Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.Type: ApplicationFiled: July 30, 2021Publication date: December 9, 2021Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kunihiro Hattori, Tetsuo Kojima, Hiroyuki Saito, Taro Miyazaki, Tetsuhiro Soeda
-
Patent number: 11150254Abstract: The inventors produced substances that neutralize the activity of a bispecific antibody having an activity of functionally substituting for FVIII, and undertook the construction of methods for measuring the reactivity of FVIII that can ensure accuracy even in the presence of this bispecific antibody. As a result, the inventors discovered that in APTT-based one-stage clotting assay, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately, and also that in APTT-based Bethesda assay, FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately.Type: GrantFiled: September 24, 2015Date of Patent: October 19, 2021Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Keiji Nogami, Midori Shima, Tetsuhiro Soeda, Takehisa Kitazawa
-
Patent number: 11078518Abstract: Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.Type: GrantFiled: September 26, 2013Date of Patent: August 3, 2021Assignees: Chugai Seiyaku Kabushiki Kaisha, Public University Corporation Nara Medical UniversityInventors: Tetsuhiro Soeda, Takehisa Kitazawa, Midori Shima
-
Publication number: 20210107995Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.Type: ApplicationFiled: December 22, 2020Publication date: April 15, 2021Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kunihiro Hattori, Tetsuo Kojima, Hiroyuki Saito, Taro Miyazaki, Tetsuhiro Soeda
-
Publication number: 20200354473Abstract: Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.Type: ApplicationFiled: July 23, 2020Publication date: November 12, 2020Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yuri Teranishi, Kazuki Kato, Hikaru Koga, Tomoyuki Igawa, Kazuki Yamaguchi, Tetsuhiro Soeda
-
Publication number: 20200277402Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.Type: ApplicationFiled: March 20, 2020Publication date: September 3, 2020Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kunihiro Hattori, Tetsuo Kojima, Hiroyuki Saito, Taro Miyazaki, Tetsuhiro Soeda
-
Patent number: 10759870Abstract: Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.Type: GrantFiled: September 27, 2018Date of Patent: September 1, 2020Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yuri Teranishi, Kazuki Kato, Hikaru Koga, Tomoyuki Igawa, Kazuki Yamaguchi, Tetsuhiro Soeda
-
Publication number: 20200223940Abstract: Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.Type: ApplicationFiled: September 27, 2018Publication date: July 16, 2020Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yuri Teranishi, Kazuki Kato, Hikaru Koga, Tomoyuki Igawa, Kazuki Yamaguchi, Tetsuhiro Soeda
-
Publication number: 20190359728Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.Type: ApplicationFiled: August 9, 2019Publication date: November 28, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kunihiro Hattori, Tetsuo Kojima, Hiroyuki Saito, Taro Miyazaki, Tetsuhiro Soeda
-
Patent number: 10450381Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: GrantFiled: April 19, 2016Date of Patent: October 22, 2019Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20190315884Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: July 2, 2019Publication date: October 17, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20190248921Abstract: The present inventors have completed the present invention by finding that an excellent anticoagulation inhibitory effect is obtained by the administration of an agent inhibiting the activation of protein C.Type: ApplicationFiled: April 23, 2019Publication date: August 15, 2019Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Takehisa Kitazawa, Aya Nakane, Kazutaka Yoshihashi, Tetsuhiro Soeda, Atsushi Muto
-
Patent number: 10302626Abstract: The present invention relates to a method for evaluating coagulability of a blood specimen obtained from a subject to whom a substance having a coagulation factor VIII-substituting activity is administered. The present invention also relates to a reagent for blood coagulation analysis, a reagent kit for blood coagulation analysis, and an apparatus for blood coagulation analysis. Furthermore, the present invention relates to an apparatus and computer program for evaluating coagulability of a blood specimen.Type: GrantFiled: October 24, 2017Date of Patent: May 28, 2019Assignees: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, CHUGAI SEIYAKU KABUSHIKI KAISHA, SYSMEX CORPORATIONInventors: Midori Shima, Keiji Nogami, Tomoko Matsumoto, Takehisa Kitazawa, Tetsuhiro Soeda, Yuka Ikeda
-
Publication number: 20190112390Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.Type: ApplicationFiled: December 20, 2018Publication date: April 18, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kunihiro Hattori, Tetsuo Kojima, Hiroyuki Saito, Taro Miyazaki, Tetsuhiro Soeda